Eli Lilly's weight loss drug retatrutide helped nearly half of participants in a phase 3 trial to lose more than 30% of their weight after two years.

The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.

A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.

Eli Lilly's retatrutide shows promise, helping obesity patients lose over 28% of their weight in a key trial.